Is Davunetide FDA approved?

Davunetide is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

VIP is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is Davunetide administered in research settings?

In research settings, Davunetide is typically administered via the intranasal or subcutaneous routes. PeptideBase does not provide dosing or administration instructions.

How is VIP administered in research settings?

In research settings, VIP is typically administered via the intranasal or intravenous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Davunetide vs VIP

Peptide Comparison

Davunetide vs VIP

Q: What is the difference between Davunetide and VIP?

Davunetide: Stabilizes microtubules by interacting with tubulin and microtubule-associated proteins. Activates SIRT1, reduces amyloid-β toxicity, and enhances synaptic plasticity. Protects against tau hyperphosphorylation. VIP: Pleiotropic neuropeptide binding VPAC1/VPAC2 receptors; suppresses neuroinflammation, regulates circadian rhythm via SCN, modulates immune response

Both are Neuro & Cognitive peptides.

Davunetide

NAP

CognitiveInvestigationalResearch Only

No providers listed yet

Full Davunetide profile →

VIP

Vasoactive Intestinal Peptide

CognitiveNot EvaluatedResearch Only

Half-life: ~1-2 minutes (plasma)

23 providers listed

Full VIP profile →

Bottom line

VIP carries stronger published evidence (RCT, 16 key studies) than Davunetide (RCT, 3); both are research compounds.

Quick Verdict

Davunetide

Half-life

—

VIP

Half-life

~1-2 minutes (plasma)

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	VIP
Further along in FDA review	Davunetide
More provider options (0 vs 23)	VIP

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Davunetide

VIP

Mechanism Family

Neuro & Cognitive

Half-life

—

~1-2 minutes (plasma)

FDA Status

investigational

not evaluated

Admin Routes

intranasal, subcutaneous

intranasal, intravenous

Availability

Research Only

Providers

None listed

23 listed

Avail. Notes

—

Endogenous 28-aa neuropeptide. No FDA-approved product. Inhaled VIP studied in Phase 2 for pulmonary arterial hypertension (Santhera); program not advanced. No NDA filed. Research use only.

Research Evidence

Davunetide

RCT · 3 key studies · most recent 2026

VIP

RCT · 16 key studies · most recent 2025

Research Citations

Davunetide

RCT2013 · Neuropsychopharmacology

Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with sch…

RCT2011 · Schizophrenia Research

Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophren…

Animal2026 · Epilepsy Res

Microtubule-stabilizing drugs suppress convulsions in a C. elegans model of CAMSAP disorders.

VIP

RCT2022 · Crit Care Med

The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failur…

RCT2020 · Cephalalgia

The effect of pituitary adenylate cyclase-activating peptide-38 and vasoactive intestinal peptide in cluster…

RCT1990 · J Urol

A clinical trial of intracavernous vasoactive intestinal peptide to induce penile erection.

Case series2024 · J Indian Assoc Pediatr Surg

Vasoactive Intestinal Polypeptide Secreting MS Neuroblastoma.

+12 more

About Davunetide

Stabilizes microtubules by interacting with tubulin and microtubule-associated proteins. Activates SIRT1, reduces amyloid-β toxicity, and enhances synaptic plasticity. Protects against tau hyperphosphorylation.

Research Areas

neuroprotectiontau stabilizationcognitive enhancementmemorysynaptic plasticity

About VIP

Pleiotropic neuropeptide binding VPAC1/VPAC2 receptors; suppresses neuroinflammation, regulates circadian rhythm via SCN, modulates immune response

Research Areas

neuroprotectionanti-inflammatory (CNS)CIRS treatmentcircadian rhythm regulation

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Davunetide

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

VIP

Reported (Unverified — Pending Clinical Review)

low blood pressurevasoactive drug interactions

No established clinical contraindications

Find Providers

Where to source these peptides

Providers offering

Davunetide

Browse directory →

Providers offering

VIP

23 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Neuro & Cognitive Comparisons

Browse all peptides →

Educational research tools — not medical advice.